EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-
BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH
OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER
RANDOMIZED, CONTROLLED TRIAL (VESPER-4)
Phase 3 – large-scale trial before approval
Conditions:
Obesity
Sponsor: Metsera Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline in body weight (kg) at Week 64, Occurrence at Week 64 of: • CCI % of reduction from baseline body weight • CCI% of reduction from baseline body weight • CCI % of reduction from baseline body weight • O CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: • Fasting triglycerides (mg/dL) • O Non-high-density lipoprotein-cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84
Percent change from baseline in body weight at Week 64
Description
Change from baseline in body weight (kg) at Week 64, Occurrence at Week 64 of: • CCI % of reduction from baseline body weight • CCI% of reduction from baseline body weight • CCI % of reduction from baseline body weight • O CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: • Fasting triglycerides (mg/dL) • O Non-high-density lipoprotein-cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 894 participants
БГ